»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China Nimustine hydrochloride CAS 55661-38-6 NIMUSTINE HCL nimustinaclorhidrato manufacturer

5th

Gold Index: 89134

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > Nimustine hydrochloride CAS 55661-38-6 NIMUSTINE HCL nimustinaclorhidrato

Nimustine hydrochloride CAS 55661-38-6 NIMUSTINE HCL nimustinaclorhidrato 

Payment Terms: T/T,L/C,WU 
Place of Origin: Sichuan, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C9H14Cl2N6O2
Production Capacity: 1T/Year
Delivery Date: within 7 days
Molecular Formula: C9H14Cl2N6O2
Molecular Weight: 309.15
Means of Transport: Ocean,Land
Packing: According to customer requi...
Brand: MOSINTER
Specification: CP/USP/EP
Alias: NIMUSTINE HCL

Ease self-conscious symptom and signs of the following diseases: brain cervical cancer, brain cancer, lung cancer, digestive tract cancer

Nimustine hydrochloride CAS 55661-38-6


Item

Index

Molecular Formula

C9H14Cl2N6O2

Molecular Weight

309.15

Specification

CP/USP/EP

Nimustine hydrochloride (Nimustine hydrochloride), relieve the role of self-conscious symptom and signs of the following diseases: brain cervical cancer, brain cancer, lung cancer, digestive tract cancer (cancer of the stomach, colon/rectal cancer, esophageal cancer, malignant lymphoma and leukemia, etc.


Clinical research

Ease self-conscious symptom and signs of the following diseases: brain cervical cancer, brain cancer, lung cancer, digestive tract cancer (cancer of the stomach, colon/rectal cancer, esophageal cancer), malignant lymphoma and leukemia, etc.

Storage method

Avoid light, cool dark save

Announcements

  1. Shall not be used for subcutaneous or intramuscular injection. 2. Intravenous drug use, if liquid leakage from blood vessels, sometimes will cause the injection site scleroma, necrosis, so careful injection in order to avoid liquid leakage from blood vessels. 3. This product with light easy to decompose, aqueous solution is not stable, dissolved immediately after use. 4. Agent mixed with him and sometimes cause change, so pay attention to.

  2. General note: (1) sometimes slow seere side effects such as bone marrow inhibition, at least six weeks after the treatment should be performed weekly clinical inspection (e.g., blood tests, liver function and renal function of procuratorial), fully the symptoms were observed. If discovery is unusual, should reduce dosage or withdrawal of appropriate treatment. In addition, the long-term use can aggravate the side effect was found to goes on, so careful medication. (2) pay attention to the infection diseases fully, the occurrence of bleeding tendency and deteriorating. (3) the pediatric drug use should be discreet, by the appearance of the side effects should be paid attention to. (4) children and patients of reproductive age, should pay attention to the influence of the gonads. 2. The following patients cannot use: (1) in patients with bone marrow suppression (2) patients with past history to our agent have severe allergies.

Safety information

Dangerous mark T Risk category code: 25

Safety instructions: 36/37/39-45

Dangerous goods transportation number: UN 2811


bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: